The Genomic Landscape of Sporadic Prolactinomas.

Copy number variation Driver mutation Loss of heterozygosity Pituitary adenoma Prolactinoma Whole exome sequencing

Journal

Endocrine pathology
ISSN: 1559-0097
Titre abrégé: Endocr Pathol
Pays: United States
ID NLM: 9009288

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 2 9 2019
medline: 5 6 2020
entrez: 2 9 2019
Statut: ppublish

Résumé

Somatic GNAS and USP8 mutations have been implicated in sporadic somatotrophinomas and corticotrophinomas, respectively. However, no genes are known to be recurrently mutated in sporadic prolactinomas. The prevalence of copy number variants (CNV), which is emerging as a mechanism of tumorigenesis in sporadic pituitary adenomas in general, is also unclear in prolactinomas. To characterize the genetic events underpinning sporadic prolactinomas, we performed whole exome sequencing of paired tumor and germline DNA from 12 prolactinoma patients. We observed recurrent large-scale CNV, most commonly in the form of copy number gains. We also identified sequence variants of interest in 15 genes. This included the DRD2, PRL, TMEM67, and MLH3 genes with plausible links to prolactinoma formation. Of the 15 genes of interest, CNV was seen at the gene locus in the corresponding tumor in 10 cases, and pituitary expression of eight genes was in the top 10% of tissues. However, none of our shortlisted somatic variants appeared to be classical driver mutations as no variant was found in more than one tumor. Future directions of research include mechanistic studies to investigate how CNV may contribute to prolactinoma formation, larger studies of relevant prolactinoma subsets according to clinical characteristics, and additional genetic investigations for aberrations not captured by whole exome sequencing.

Identifiants

pubmed: 31473917
doi: 10.1007/s12022-019-09587-0
pii: 10.1007/s12022-019-09587-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

318-328

Subventions

Organisme : Royal Adelaide Hospital
ID : 8412
Organisme : Royal Adelaide Hospital
ID : 73-05-28-06-17

Références

Pituitary. 2008;11(3):231-45
pubmed: 18183490
Front Endocrinol (Lausanne). 2018 Nov 30;9:706
pubmed: 30555413
Mol Cell Endocrinol. 2017 May 5;446:81-90
pubmed: 28214592
J Clin Endocrinol Metab. 2017 Nov 1;102(11):3928-3932
pubmed: 28938458
Nat Genet. 2001 Oct;29(2):137-8
pubmed: 11586295
J Clin Endocrinol Metab. 2019 Oct 1;104(10):4676-4682
pubmed: 31162547
Eur J Hum Genet. 2018 Sep;26(9):1266-1271
pubmed: 29891882
Nat Genet. 2015 Jan;47(1):31-8
pubmed: 25485838
J Clin Endocrinol Metab. 2013 Apr;98(4):E796-800
pubmed: 23450047
Endocr Relat Cancer. 2007 Sep;14(3):901-6
pubmed: 17914118
Cell Res. 2016 Nov;26(11):1255-1259
pubmed: 27670697
J Clin Endocrinol Metab. 2017 Feb 1;102(2):566-575
pubmed: 27854551
Eur J Endocrinol. 1999 Jun;140(6):573-6
pubmed: 10366412
Endocr Relat Cancer. 2015 Oct;22(5):745-57
pubmed: 26187128
J Endocrinol. 2019 Feb 1;240(2):R21-R45
pubmed: 30530903
Cancer Res. 2018 Oct 15;78(20):5970-5979
pubmed: 30154148
Blood. 2018 Aug 30;132(9):948-961
pubmed: 29967129
Nat Genet. 2014 Feb;46(2):161-5
pubmed: 24413733
Curr Neurol Neurosci Rep. 2018 Feb 2;18(1):4
pubmed: 29396598
Hum Mol Genet. 2019 Mar 15;28(6):1023-1037
pubmed: 30445560
BMC Cancer. 2015 Apr 12;15:272
pubmed: 25884948
N Engl J Med. 2014 Dec 18;371(25):2363-74
pubmed: 25470569
Endocr Pathol. 2007 Winter;18(4):217-22
pubmed: 18026859
Clin Biochem Rev. 2018 Feb;39(1):17-28
pubmed: 30072819
J Clin Endocrinol Metab. 1993 Sep;77(3):765-9
pubmed: 8396579
J Neurooncol. 2014 Jan;116(1):83-8
pubmed: 24135847
J Neurooncol. 2010 Aug;99(1):25-32
pubmed: 20063113
N Engl J Med. 2013 Nov 28;369(22):2105-14
pubmed: 24283224
Neuron. 1997 Jul;19(1):103-13
pubmed: 9247267
Am J Hum Genet. 2017 May 4;100(5):817-823
pubmed: 28413019
J Clin Endocrinol Metab. 1994 Jan;78(1):89-93
pubmed: 8288721
Clin Cancer Res. 2017 Apr 1;23(7):1841-1851
pubmed: 27707790
Endocrinology. 2017 Jul 1;158(7):2284-2291
pubmed: 28486603
Eur J Endocrinol. 2017 May;176(5):635-644
pubmed: 28220018

Auteurs

Sunita M C De Sousa (SMC)

Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia. Sunita.DeSousa@sa.gov.au.
Department of Genetics and Molecular Pathology, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia. Sunita.DeSousa@sa.gov.au.
School of Medicine, University of Adelaide, Adelaide, Australia. Sunita.DeSousa@sa.gov.au.

Paul P S Wang (PPS)

ACRF Cancer Genomics Facility, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia.

Stephen Santoreneos (S)

Department of Neurosurgery, Royal Adelaide Hospital, Adelaide, Australia.

Angeline Shen (A)

Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Australia.
Department of Medicine, University of Melbourne, Melbourne, Australia.

Christopher J Yates (CJ)

Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Australia.
Department of Medicine, University of Melbourne, Melbourne, Australia.

Milena Babic (M)

Department of Genetics and Molecular Pathology, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia.

Leila Eshraghi (L)

Department of Genetics and Molecular Pathology, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia.
ACRF Cancer Genomics Facility, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia.
School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Jinghua Feng (J)

ACRF Cancer Genomics Facility, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia.
School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Barbara Koszyca (B)

Department of Anatomical Pathology, Royal Adelaide Hospital, Adelaide, Australia.

Samuel Roberts-Thomson (S)

Department of Anatomical Pathology, Royal Melbourne Hospital, Melbourne, Australia.

Andreas W Schreiber (AW)

ACRF Cancer Genomics Facility, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia.
School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
School of Biological Sciences, University of Adelaide, Adelaide, Australia.

David J Torpy (DJ)

Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
School of Medicine, University of Adelaide, Adelaide, Australia.

Hamish S Scott (HS)

Department of Genetics and Molecular Pathology, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia.
School of Medicine, University of Adelaide, Adelaide, Australia.
ACRF Cancer Genomics Facility, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia.
School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH